Literature DB >> 16227285

Combinatorial approach to hepadnavirus-like particle vaccine design.

Jean-Noel Billaud1, Darrell Peterson, Margaret Barr, Antony Chen, Matti Sallberg, Fermin Garduno, Phillip Goldstein, Wendy McDowell, Janice Hughes, Joyce Jones, David Milich.   

Abstract

The particulate hepatitis core protein (HBcAg) represents an efficient carrier platform with many of the characteristics uniquely required for the delivery of weak immunogens to the immune system. Although the HBcAg is highly immunogenic, the existing HBcAg-based platform technology has a number of theoretical and practical limitations, most notably the "preexisting immunity" and "assembly" problems. To address the assembly problem, we have developed the core protein from the woodchuck hepadnavirus (WHcAg) as a new particulate carrier platform system. WHcAg appears to tolerate insertions of foreign epitopes at a greater number of positions than HBcAg. For example, both within the external loop region and outside the loop region a total of 17 insertion sites were identified on WHcAg. Importantly, the identification of an expanded number of insertion sites was dependent on additional modifications to the C terminus that appear to stabilize the various internal insertions. Indeed, 21 separate C-terminal modifications have been generated that can be used in combination with the 17 insertion sites to ensure efficient hybrid WHcAg particle assembly. This combinatorial technology is also dependent on the sequence of the heterologous insert. Therefore, the three variables of insert position, C terminus, and epitope sequence are relevant in the design of hybrid WHcAg particles for vaccine purposes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16227285      PMCID: PMC1262598          DOI: 10.1128/JVI.79.21.13656-13666.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  The crystal structure of the human hepatitis B virus capsid.

Authors:  S A Wynne; R A Crowther; A G Leslie
Journal:  Mol Cell       Date:  1999-06       Impact factor: 17.970

2.  Insertion of foreign epitopes in HBcAg: how to make the chimeric particle assemble.

Authors:  L I Karpenko; V A Ivanisenko; I A Pika; N A Chikaev; A M Eroshkin; T A Veremeiko; A A Ilyichev
Journal:  Amino Acids       Date:  2000       Impact factor: 3.520

3.  Formation of immunogenic virus-like particles by inserting epitopes into surface-exposed regions of hamster polyomavirus major capsid protein.

Authors:  A Gedvilaite; C Frömmel; K Sasnauskas; B Micheel; M Ozel; O Behrsing; J Staniulis; B Jandrig; S Scherneck; R Ulrich
Journal:  Virology       Date:  2000-07-20       Impact factor: 3.616

4.  Comparative antigenicity and immunogenicity of hepadnavirus core proteins.

Authors:  Jean-Noel Billaud; Darrell Peterson; Florian Schödel; Antony Chen; Matti Sallberg; Fermin Garduno; Phillip Goldstein; Wendy McDowell; Janice Hughes; Joyce Jones; David Milich
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

5.  Removal of endotoxin from recombinant protein preparations.

Authors:  S Liu; R Tobias; S McClure; G Styba; Q Shi; G Jackowski
Journal:  Clin Biochem       Date:  1997-08       Impact factor: 3.281

6.  Molecular basis for the interaction of the hepatitis B virus core antigen with the surface immunoglobulin receptor on naive B cells.

Authors:  U Lazdina; T Cao; J Steinbergs; M Alheim; P Pumpens; D L Peterson; D R Milich; G Leroux-Roels; M Sällberg
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

7.  Exposure of RNA templates and encapsidation of spliced viral RNA are influenced by the arginine-rich domain of human hepatitis B virus core antigen (HBcAg 165-173).

Authors:  Sophie Le Pogam; Pong Kian Chua; Margaret Newman; Chiaho Shih
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

8.  Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles.

Authors:  B Chackerian; D R Lowy; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

9.  Immunization with hybrid hepatitis B virus core particles carrying circumsporozoite antigen epitopes protects mice against Plasmodium yoelii challenge.

Authors:  F Schödel; D Peterson; D R Milich; Y Charoenvit; J Sadoff; R Wirtz
Journal:  Behring Inst Mitt       Date:  1997-02

10.  Nucleolar localization of human hepatitis B virus capsid protein.

Authors:  Bo Ning; Chiaho Shih
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

View more
  25 in total

1.  Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7.

Authors:  Jerri do Carmo Caldeira; Alexander Medford; Rhonda C Kines; Christopher A Lino; John T Schiller; Bryce Chackerian; David S Peabody
Journal:  Vaccine       Date:  2010-04-29       Impact factor: 3.641

Review 2.  Review on the identification and role of Toxoplasma gondii antigenic epitopes.

Authors:  Yanhua Wang; Guangxiang Wang; Jianping Cai; Hong Yin
Journal:  Parasitol Res       Date:  2015-11-19       Impact factor: 2.289

3.  Comparative antigenicity and immunogenicity of hepadnavirus core proteins.

Authors:  Jean-Noel Billaud; Darrell Peterson; Florian Schödel; Antony Chen; Matti Sallberg; Fermin Garduno; Phillip Goldstein; Wendy McDowell; Janice Hughes; Joyce Jones; David Milich
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

4.  Interaction of the hepatitis B core antigen and the innate immune system.

Authors:  Byung O Lee; Amy Tucker; Lars Frelin; Matti Sallberg; Joyce Jones; Cory Peters; Janice Hughes; David Whitacre; Bryan Darsow; Darrell L Peterson; David R Milich
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

5.  Advantages to the use of rodent hepadnavirus core proteins as vaccine platforms.

Authors:  Jean-Noel Billaud; Darrell Peterson; Byung O Lee; Toshiyuki Maruyama; Antony Chen; Matti Sallberg; Fermin Garduño; Phillip Goldstein; Janice Hughes; Joyce Jones; David Milich
Journal:  Vaccine       Date:  2006-11-17       Impact factor: 3.641

Review 6.  Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platform.

Authors:  John P O'Rourke; David S Peabody; Bryce Chackerian
Journal:  Curr Opin Virol       Date:  2015-03-29       Impact factor: 7.090

7.  Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge.

Authors:  Jeanne H Schickli; David C Whitacre; Roderick S Tang; Jasmine Kaur; Heather Lawlor; Cory J Peters; Joyce E Jones; Darrell L Peterson; Michael P McCarthy; Gary Van Nest; David R Milich
Journal:  J Clin Invest       Date:  2015-03-09       Impact factor: 14.808

8.  Hepatitis B virus nucleocapsid but not free core antigen controls viral clearance in mice.

Authors:  Yi-Jiun Lin; Hui-Lin Wu; Ding-Shinn Chen; Pei-Jer Chen
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

Review 9.  Use of hepadnavirus core proteins as vaccine platforms.

Authors:  David C Whitacre; Byung O Lee; David R Milich
Journal:  Expert Rev Vaccines       Date:  2009-11       Impact factor: 5.217

10.  Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2.

Authors:  David S Peabody; Brett Manifold-Wheeler; Alexander Medford; Sheldon K Jordan; Jerri do Carmo Caldeira; Bryce Chackerian
Journal:  J Mol Biol       Date:  2008-04-27       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.